Selected publications:

Thompson RN, Southall E, Daon Y, Lovell-Read FA, Iwami S, Thompson CP*, Obolski U*. The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants. Frontiers in Immunology. 2023 13:1049458. doi: https://doi.org/10.3389/fimmu.2022.1049 PMID: 36713397 *Joint senior author

McNaughton AL, Paton RS, Edmans M et al… Thompson CP. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight. 2022 7(13):e156372. doi: 10.1172/jci.insight.156372. PMID: 35608920

Wellens J, Edmans M, Obolski U, McGregor CG, Simmonds P, Turner M, Jarvis L, Skelly D, Dunachie S, Barnes E, Eyre DW, Colombel JF, Wong SY, Klenerman P, Lindsay JO, Satsangi J, Thompson CP. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut. 2022 71 (9), 1919-1922 doi: 10.1136/gutjnl-2021-326312. PMID: 34911744.

Bolton JS, Klim H, Wellens J, Edmans M, Obolski U, Thompson CP. An Antigenic Thrift-Based Approach to Influenza Vaccine Design. Vaccines. 2021 9(6):657. doi:10.3390/vaccines9060657 PMID: 34208489

Dejnirattisai et al. ‘The antigenic anatomy of SARS-CoV-2 receptor binding domain.’ Cell. 2021 184(8):2183-2200.e22. doi: https://doi.org/10.1016/j.cell.2021.02.032. PMID: 33756110

Ogbe et al. ‘T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.’ Nature Communications (2021) 12, 2055 doi: https://doi.org/10.1038/s41467-021-21856-3

 Wing et al. ‘Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.’ Cell Reports (2021) 20;35(3):109020. doi: https://doi.org/10.1016/j.celrep.2021.109020.

Thompson CP, Grayson NE, Paton RS et al... Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance. 2020 25(42):2000685. doi: 10.2807/1560-7917.ES.2020.25.42.2000685. PMID: 33094713.

Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O'Connor D, Bowden TA, Pybus OG, Pollard AJ, Temperton NJ, Lambe T, Gilbert SC, Gupta S. A naturally protective epitope of limited variability as an influenza vaccine target. Nature Communications. 2018 21;9(1):3859. doi: 10.1038/s41467-018-06228-8. PMID: 30242149

Thompson CP & Oboski U. ‘Influenza vaccination and the diversity paradox’. Human Vaccines & Immunotherapeutics (2018) 21:1-5 doi: https://doi.org/10.1080/21645515.2018.1504596

For a full list please see Google Scholar.